



(for immediate release)

## JANA CARE RECEIVES US FDA CLEARANCE FOR AINA HbA1c MONITORING SYSTEM 2

**Boston, MA – 26<sup>th</sup> March 2020** – Jana Care today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Aina HbA1c Monitoring System 2, an automated glycosylated hemoglobin (HbA1c) test system. Glycosylated hemoglobin is primarily used to determine the three-month average blood sugar level and can be used to monitor long term glycemic control of persons previously diagnosed with diabetes. The system is among the first smartphone-based blood testing devices approved by the US FDA.

The system combines reliable boronate affinity test chemistry and a proprietary smartphone-powered, cloud-connected device, resulting in efficient, accurate, and accessible HbA1c monitoring. Unlike other popular HbA1c tests that rely on immunoassay methods, the Aina HbA1c Monitoring System 2's boronate affinity chemistry accurately assesses HbA1c levels in individuals with hemoglobin variants, which are disproportionately high among individuals with African (18%), Indian (18%), Southeast Asian (7%), and Mediterranean (5%) ethnicities. The Aina HbA1c Monitoring System 2's cloud connection automatically uploads and organizes patient test data, reducing operator administrative burden.

"50% of Type 2 Diabetes globally remains undiagnosed and barely 10% of patients meet therapy goals. Our novel point-of-care test platform enables early detection and management of Type 2 Diabetes at a fraction of current costs," said Sidhant Jena, Jana Care CEO. "FDA approval of the Aina HbA1c Monitoring System 2 offers US healthcare professionals, especially small medical clinics, a new and cost-effective option to better serve their diabetic patients at the point of care."

### About Jana Care

Founded in 2011, Jana Care ([www.janacare.com](http://www.janacare.com)) is a medical technology company that develops point-of-care diagnostics and digital coaching programs for the screening and management chronic diseases. Its novel FDA-cleared and CE-marked diagnostic platform, Aina, enables testing of HbA1c, Blood Glucose, Lipid Profile and Hemoglobin using fingerstick blood samples, with new tests for NT-proBNP and Serum Creatinine in development. The company has also developed the Habits Program, a digital coaching program for patients with Diabetes and Heart Failure, in collaboration with leading academic medical centers globally.

Jana Care is headquartered in Boston, USA, and has established an ISO 13485 certified production facility in Bangalore, India.

Press contacts:  
Sidhant Jena  
CEO, Jana Care  
[sjena@janacare.com](mailto:sjena@janacare.com)